Given that the phenotype was not striking (particularly at the end of the tumor study) between Ogr1 WT and Ogr1 KO animals, we envision targeting the OGR1 protein as a combination therapeutic strategy where a standard of care chemotherapeutic would synergize with a stroma-targeting OGR1 antagonist. This evidence concerns the gene GPR68 and neoplasm.